Indication
Pneumonia due to Staphylococcus aureus
Pneumonia due to Staphylococcus aureus is an acute lower respiratory tract infection characterized by bacterial invasion and inflammation of the pulmonary parenchyma. Read more about Pneumonia due to Staphylococcus aureus
27 drugs 26 manufacturers
Drugs that treat it
Common Pneumonia due to Staphylococcus aureus therapies.
AZITHROMYCIN
AZITHROMYCIN
AZITHROMYCIN
AZITHROMYCIN
AZITHROMYCIN
AMOXICILLIN-CLAVULANATE POT ER (amoxicillin/potassium clavulanate)
CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate)
CEFTAROLINE FOSAMIL (ceftaroline fosamil acetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPneumonia due to Staphylococcus aureus is an acute lower respiratory tract infection characterized by bacterial invasion and inflammation of the pulmonary parenchyma.
It affects hospitalized or mechanically ventilated patients, individuals with underlying chronic illnesses, and healthy hosts following viral respiratory infections such as influenza.
Pathophysiologically, the organism releases potent toxins and enzymes that induce widespread tissue destruction, alveolar infiltration, and intense host inflammatory responses.
Defining clinical features often include high fever, productive cough, dyspnea, and rapid progression to severe complications such as lung abscesses, necrotizing pneumonia, pneumatoceles, empyema, and respiratory failure.
- nih.gov
Pneumonia due to Staphylococcus aureus is an acute lower respiratory tract infection characterized by bacterial invasion and inflammation of the pulmonary parenchyma
- nih.gov
It affects hospitalized or mechanically ventilated patients, individuals with underlying chronic illnesses, and healthy hosts following viral respiratory infections such as influenza
- nih.gov
It affects hospitalized or mechanically ventilated patients, individuals with underlying chronic illnesses, and healthy hosts following viral respiratory infections such as influenza
- mdsearchlight.com
Pathophysiologically, the organism releases potent toxins and enzymes that induce widespread tissue destruction, alveolar infiltration, and intense host inflammatory responses
- nih.gov
Pathophysiologically, the organism releases potent toxins and enzymes that induce widespread tissue destruction, alveolar infiltration, and intense host inflammatory responses
- nih.gov
Defining clinical features often include high fever, productive cough, dyspnea, and rapid progression to severe complications such as lung abscesses, necrotizing pneumonia, pneumatoceles, empyema, and respiratory failure
- nih.gov
Defining clinical features often include high fever, productive cough, dyspnea, and rapid progression to severe complications such as lung abscesses, necrotizing pneumonia, pneumatoceles, empyema, and respiratory failure
Personalize your experience
Follow Pneumonia due to Staphylococcus aureus and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.